QuidelOrtho Corp. 10-Q Summary: Q2 2025
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for QuidelOrtho Corporation for the quarter ended June 29, 2025. The company operates in the diagnostics sector with reportable segments in North America, EMEA, and China. The reporting period includes 13 weeks. As of July 30, 2025, there were 67,900,466 shares of common stock outstanding.
Key Financial Metrics
| Metric (in millions) | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $613.9 | $1,306.7 | $637.0 | $1,348.0 |
| Net Loss | $(255.4) | $(268.1) | $(147.7) | $(1,853.7) |
| Operating Loss | $(180.7) | $(148.1) | $(117.5) | $(1,875.5) |
| Adjusted EBITDA (Total Segments) | $258.0 | $567.7 | $267.4 | $573.2 |
| Cash and Cash Equivalents | $151.7 | $151.7 | $98.3 | $107.5 |
| Total Debt (Current + Long-term) | $2,606.3 | $2,606.3 | $2,483.1 | $2,483.1 |
| Operating Cash Flow | N/A | $18.8 | N/A | $(98.6) |
Margins: Gross margin (excluding amortization) improved to 44.8% in Q2 2025 compared to 43.3% in Q2 2024. Cost of sales decreased to 55.2% of revenue in Q2 2025.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 4% in Q2 2025 and 3% YTD compared to the prior year. This was driven by a 61% drop in Donor Screening revenue (due to the planned wind-down of the U.S. portfolio) and a 21% decline in Point of Care revenue (lower sales of SARS antigen assays). These declines were partially offset by growth in Labs (4%) and Immunohematology (4%).
- Restructuring Charges: The company recorded significant "Restructuring, integration and other charges" of $178.9 million in Q2 2025 ($195.0 million YTD), compared to $30.9 million in Q2 2024. This increase is primarily due to the "Optimization Plan" (cost-reduction initiatives) and the "Savanna Exit" (discontinuation of the Savanna platform), which included $148.6 million in asset impairments/write-offs.
- Profitability: While the company reported a net loss of $255.4 million in Q2 2025, this is a significant improvement over the $1.85 billion net loss in the same period in 2024, which included a $1.74 billion non-cash goodwill impairment charge.
- Segment Performance: North America Adjusted EBITDA declined 14% QoQ due to the donor screening wind-down. Conversely, EMEA Adjusted EBITDA grew 51% and China grew 18%, driven by revenue increases and cost-savings initiatives.
Guidance, Outlook, and Risks
- Optimization Plan: Launched in Q2 2025, this multi-year plan aims to realign costs with revenue expectations. Cumulative pretax charges are expected to be approximately $100 million through 2027, with anticipated net cost savings of $50 million.
- Savanna Exit: The company is discontinuing the development of the Savanna platform, expected to be substantially complete by the first half of 2027.
- Strategic Acquisitions: The company expressed intent to acquire LEX Diagnostics.
- Liquidity: Management believes current cash ($151.7 million) and available credit ($397.3 million under the Revolving Credit Facility) are sufficient to fund operations for the next 12 months.
- Risks:
- Legal Proceedings: Ongoing putative class action and derivative lawsuits regarding COVID-19 test sales and the Savanna RVP4 assay. The company cannot estimate potential losses.
- Internal Controls: Disclosure controls and procedures were deemed not effective as of June 29, 2025, due to previously reported material weaknesses in internal control over financial reporting. Remediation is ongoing.
- Macroeconomics: Potential adverse effects from new U.S. tariffs announced in April 2025 and retaliatory measures.
Investor Verification Checklist
- Restructuring Impact: Verify the timeline and cash outflow implications of the $100 million "Optimization Plan" and the "Savanna Exit."
- Internal Control Remediation: Monitor progress on remediation of material weaknesses in internal controls, specifically regarding the new SAP ERP implementation.
- Respiratory Revenue Volatility: Assess the sustainability of revenue given the 61% drop in Donor Screening and the seasonal nature of respiratory products (flu/RSV/COVID).
- Debt Covenants: Confirm continued compliance with the Credit Agreement's leverage and interest coverage ratios, especially given the recent restructuring charges.
- Legal Exposure: Track developments in the Bristol County and Whitfield/Pinkney lawsuits regarding potential damages.